923949-15-9

Upstream product

• 31181-89-2 5-chloro-2-pyridine carboxaldehyde 
• 137789-54-9 diethyl {2-[(4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}phosphonate 
• 947373-28-6 (2E)-3-(5-chloropyridin-2-yl)acrylic acid trifluoroacetic acid salt 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 

Downstream Products

• 923949-24-0 (4S)-4-benzyl-3-{[(3R,4R)-1-benzyl-4-(5-chloropyridin-2-yl)pyrrolidin-3-yl]carbonyl}-1,3-oxazolidin-2-one 
• 923949-16-0 (4S)-4-benzyl-3-{[(3S,4S)-1-benzyl-4-(5-chloropyridin-2-yl)pyrrolidin-3-yl]carbonyl}-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

PIPERAZINE DERIVATIVE

[Problem] To provide a compound useful as an MC4 receptor agonist. [Solution] The present inventors have made studies on MC4 receptor agonists. As a result, it is confirmed that a piperazine derivative has an MC4 receptor agonist activity, which leads to the accomplishment of the present invention. The piperazine derivative according to the present invention has an MC4 receptor agonist activity, and therefore can be used as a prophylactic or therapeutic agent for disturbance of urination in bladder and urinary tract diseases, particularly underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-sphincter dyssynergia and prostatic hyperplasia.

PIPERAZINE DERIVATIVE

[Problem] To provide a compound which can be used as an MC4 receptor agonist. [Means for Solution] The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS

The present invention relates to a class of compounds of general formula (I) and the salts, hydrates, solvates, polymorphs and prodrugs wherein n, R6, R7 and R10 are as defined herein and especially to MCR4 agonist compounds of formula (I), to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES

The present invention relates to a class of melanocortin MCR4 agonists of general formula (I), wherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.